NCT06785636
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Recruiting · Phase 1, Phase 2 · Pathos AI, Inc. · registry updated 2026-08-20
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Inclusion
- ≥18 years of age
- Histologic documentation of prostate adenocarcinoma
- Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable
Exclusion
- Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate biopsy.
- Any liver metastases confirmed by biopsy or evidence of lesions \>1 cm consistent with liver metastases on imaging.
- Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Cycle 1 Day 1 or 5 half-lives (whichever is shorter).
- Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complications.
- a only -key inclusion criteria:
- Must have received at least 2 cycles of PLUVICTO®